TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Lexaria Bioscience ( (LEXX) ) has provided an update.
Lexaria Bioscience Corp. announced the successful closing of a $4.0 million registered direct offering, priced at-the-market under Nasdaq rules. The proceeds from this offering are intended to support Lexaria’s 2026 research and development and business development plans, enhancing the company’s ability to execute on R&D initiatives that drive intellectual property and shareholder value.
The most recent analyst rating on (LEXX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Lexaria Bioscience stock, see the LEXX Stock Forecast page.
More about Lexaria Bioscience
Lexaria Bioscience Corp. is a global innovator in drug delivery platforms, primarily known for its patented DehydraTECH technology. This platform enhances the oral delivery of drugs by improving bio-absorption, reducing side effects, and facilitating drug delivery across the blood-brain barrier. The company maintains a strong intellectual property portfolio with 50 patents granted worldwide.
Average Trading Volume: 487,430
Technical Sentiment Signal: Strong Sell
Current Market Cap: $20.54M
For an in-depth examination of LEXX stock, go to TipRanks’ Overview page.